Literature DB >> 3654709

Synovectomy of the rheumatoid knee using intra-articular injection of dysprosium-165-ferric hydroxide macroaggregates.

C B Sledge1, J D Zuckerman, S Shortkroff, M R Zalutsky, P Venkatesan, M A Snyder, W P Barrett.   

Abstract

One hundred and eleven patients who had seropositive rheumatoid arthritis and persistent synovitis of the knee were treated with intra-articular injection of 270 millicuries of dysprosium-165 bound to ferric hydroxide macroaggregates. A two-year follow-up was available for fifty-nine of the treated knees. Thirty-nine had a good result; nine, a fair result; and eleven, a poor result. Of the twenty-five knees that had Stage-I radiographic changes, nineteen had a good result. Of the thirty-four knees that had Stage-II radiographic changes, twenty showed a good result. Systemic spread of the radioactivity from the injected joint was minimum. The mean whole-body dose was calculated to be 0.3 rad and that to the liver twenty-four hours after injection, 3.2 rads. The results indicated that dysprosium-165-ferric hydroxide macroaggregate is an effective agent for performing radiation synovectomy, particularly in knees that have Stage-I radiographic changes. Because of the minimum rate of systemic spread of the dysprosium-165, it offers a definite advantage over agents that previously have been used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3654709

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  2 in total

Review 1.  Radiation synovectomy revisited.

Authors:  E Deutsch; J W Brodack; K F Deutsch
Journal:  Eur J Nucl Med       Date:  1993-11

2.  MR evaluation of radiation synovectomy of the knee by means of intra-articular injection of holmium-166-chitosan complex in patients with rheumatoid arthritis: results at 4-month follow-up.

Authors:  Sang Hoon Lee; Jin Suck Suh; Ho Seok Kim; Jong Doo Lee; Jungsik Song; Soo Kon Lee
Journal:  Korean J Radiol       Date:  2003 Jul-Sep       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.